Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
Public ClinicalTrials.gov record NCT02330965. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (AMS04)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary goal of this study is to evaluate the effects of BAF312 (siponimod) on select immune and neuronal (nerve) cells by examining laboratory specimens (blood and/or spinal fluid) at multiple time points, prior to, and following the initiation of BAF312 or placebo treatment, in patients with Secondary Progressive Multiple Sclerosis (SPMS) who are enrolled in a clinical trial (NCT01665144) to evaluate the effectiveness and safety of BAF312.
Study identification
- NCT ID
- NCT02330965
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014
- Primary completion
- Jul 11, 2017
- Completion
- Jul 11, 2017
- Last update posted
- Nov 8, 2020
2014 – 2017
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Jordan Research & Education Institute: Sutter Alta Bates Summit | Berkeley | California | 94705 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| University of California, Davis | Sacramento | California | 95817 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| University of Michigan Health System -Multiple Sclerosis Center | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Minneapolis Clinic of Neurology | Golden Valley | Minnesota | 55422 | — |
| University of New Mexico: Health Sciences Center | Albuquerque | New Mexico | 87131 | — |
| South Shore Neurologic Associates - Multiple Sclerosis Care Center | Patchogue | New York | 11772 | — |
| Carolinas Medical Center (CMC) | Charlotte | North Carolina | 28207 | — |
| Cleveland Clinic: Mellen Center for Multiple Sclerosis | Cleveland | Ohio | 44195 | — |
| Providence Multiple Sclerosis Center | Portland | Oregon | 97225 | — |
| Swedish Neuroscience Institute | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Secondary Progressive Multiple Sclerosis trials
Other public records listing Secondary Progressive Multiple Sclerosis. Sorted by last update posted; newest first. Not a recommendation.
- NCT06292923: A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients Active, not recruiting
- NCT07299019: A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis Recruiting
- NCT05327322: Functional Outcomes From Diets in Multiple Sclerosis Active, not recruiting
- NCT06372145: A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02330965, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2020 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02330965 live on ClinicalTrials.gov.